Perspective Therapeutics, Inc. Board of Directors

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

Ms. Annie J. Cheng

Ms. Annie J. Cheng

Vice President of Investor Relations

Mr. Andrew Bright

Mr. Andrew Bright

Executive Vice President of Brachytherapy

Mr. Shane Cobb

Mr. Shane Cobb

Executive Vice President of Operations

Mr. Amos Hedt BA, PGradDip

Mr. Amos Hedt BA, PGradDip

Chief Business Strategy Officer

Dr. Frances L. Johnson M.D.

Dr. Frances L. Johnson M.D.

Chief Innovation Officer

Mr. Jonathan R. Hunt

Mr. Jonathan R. Hunt

Chief Accounting Officer

Mr. Juan Graham

Mr. Juan Graham

Chief Financial Officer

Comments